• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Rho GTPases 作为癌症治疗靶点的研究进展(综述)。

Rho GTPases as therapeutic targets in cancer (Review).

机构信息

Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, Bernal B1876BXD, Buenos Aires, Argentina.

出版信息

Int J Oncol. 2017 Oct;51(4):1025-1034. doi: 10.3892/ijo.2017.4093. Epub 2017 Aug 9.

DOI:10.3892/ijo.2017.4093
PMID:28848995
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5592879/
Abstract

Rho GTPases are key molecular switches controlling the transduction of external signals to cytoplasmic and nuclear effectors. In the last few years, the development of genetic and pharmacological tools has allowed a more precise definition of the specific roles of Rho GTPases in cancer. The aim of the present review is to describe the cellular functions regulated by these proteins with focus in deregulated signals present in malignant tumors. Finally, we describe the state of the art in search of different experimental therapeutic strategies with Rho GTPases as molecular targets.

摘要

Rho GTPases 是控制外部信号向细胞质和核效应物转导的关键分子开关。在过去的几年中,遗传和药理学工具的发展使得 Rho GTPases 在癌症中的特定作用能够得到更精确的定义。本文的目的是描述这些蛋白调节的细胞功能,并重点介绍恶性肿瘤中存在的失调信号。最后,我们描述了 Rho GTPases 作为分子靶点的不同实验治疗策略的研究现状。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/436a/5592879/eaa864e970f1/IJO-51-04-1025-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/436a/5592879/eaa864e970f1/IJO-51-04-1025-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/436a/5592879/eaa864e970f1/IJO-51-04-1025-g00.jpg

相似文献

1
Rho GTPases as therapeutic targets in cancer (Review).Rho GTPases 作为癌症治疗靶点的研究进展(综述)。
Int J Oncol. 2017 Oct;51(4):1025-1034. doi: 10.3892/ijo.2017.4093. Epub 2017 Aug 9.
2
[Rho GTPases as therapeutic targets in cancer and other human diseases].[Rho GTP酶作为癌症及其他人类疾病的治疗靶点]
Medicina (B Aires). 2010;70(6):555-64.
3
[Rho GTPases as molecular targets in cancer. Strategies and therapeutic opportunities].[作为癌症分子靶点的Rho GTP酶。策略与治疗机遇]
Medicina (B Aires). 2017;77(6):497-504.
4
Targeting Rho GTPase signaling for cancer therapy.针对 Rho GTPase 信号通路的癌症治疗策略。
Future Oncol. 2012 Feb;8(2):165-77. doi: 10.2217/fon.11.143.
5
Approaches of targeting Rho GTPases in cancer drug discovery.癌症药物研发中靶向Rho GTP酶的方法。
Expert Opin Drug Discov. 2015;10(9):991-1010. doi: 10.1517/17460441.2015.1058775. Epub 2015 Jun 18.
6
Deregulation of Rho GTPases in cancer.癌症中Rho GTP酶的失调。
Small GTPases. 2016 Jul 2;7(3):123-38. doi: 10.1080/21541248.2016.1173767. Epub 2016 Apr 22.
7
Rho GTPases in hematopoietic stem cell functions.造血干细胞功能中的Rho GTP酶
Curr Opin Hematol. 2009 Jul;16(4):249-54. doi: 10.1097/MOH.0b013e32832c4b80.
8
Rho GTPases: Anti- or pro-neoplastic targets?Rho GTP酶:抗肿瘤还是促肿瘤靶点?
Oncogene. 2017 Jun 8;36(23):3213-3222. doi: 10.1038/onc.2016.473. Epub 2016 Dec 19.
9
Rho GTPases: promising cellular targets for novel anticancer drugs.Rho GTP酶:新型抗癌药物颇具前景的细胞靶点。
Curr Cancer Drug Targets. 2006 Feb;6(1):1-14.
10
Rho GTPases: potential candidates for anticancer therapy.Rho GTP酶:抗癌治疗的潜在候选对象。
Cancer Lett. 2004 Apr 8;206(2):181-91. doi: 10.1016/j.canlet.2003.08.035.

引用本文的文献

1
Probing the protrusions: lamellipodia and filopodia in cancer invasion and beyond.探索突起结构:板状伪足和丝状伪足在癌症侵袭及其他方面的作用
Mechanobiol Med. 2024 Mar 20;2(2):100064. doi: 10.1016/j.mbm.2024.100064. eCollection 2024 Jun.
2
High expression of RHOF is an effective diagnostic marker and a potential prognostic indicator for primary mediastinal large B-cell lymphoma.RHOF的高表达是原发性纵隔大B细胞淋巴瘤的有效诊断标志物和潜在的预后指标。
Virchows Arch. 2024 Dec 4. doi: 10.1007/s00428-024-03993-4.
3
An allosteric inhibitor of RhoGAP class-IX myosins suppresses the metastatic features of cancer cells.

本文引用的文献

1
Post translational modifications of Rab GTPases.Rab GTP 酶的翻译后修饰。
Small GTPases. 2018 Mar 4;9(1-2):49-56. doi: 10.1080/21541248.2017.1299270. Epub 2017 Apr 20.
2
Discovery and characterization of small molecule Rac1 inhibitors.小分子Rac1抑制剂的发现与表征
Oncotarget. 2017 May 23;8(21):34586-34600. doi: 10.18632/oncotarget.16656.
3
Simultaneous Interference with HER1/EGFR and RAC1 Signaling Drives Cytostasis and Suppression of Survivin in Human Glioma Cells in Vitro.同时干扰HER1/EGFR和RAC1信号通路可驱动体外人胶质瘤细胞的细胞停滞并抑制生存素
一种变构 RhoGAP 类肌球蛋白的抑制剂抑制了癌细胞的转移特征。
Nat Commun. 2024 Nov 16;15(1):9947. doi: 10.1038/s41467-024-54181-6.
4
Novel inhibitor against Rac1 for therapeutic approach in prevention of breast cancer progression.新型 Rac1 抑制剂在预防乳腺癌进展中的治疗应用。
Sci Rep. 2024 Oct 23;14(1):25083. doi: 10.1038/s41598-024-75351-y.
5
IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers.IKKβ 激酶抑制剂 BAY 11-7082 增强 RAS 驱动型癌症的抗肿瘤作用。
J Transl Med. 2024 Jul 9;22(1):642. doi: 10.1186/s12967-024-05384-4.
6
Pan‑cancer analysis identified ARHGAP23 as a potential biomarker for pancreatic adenocarcinoma.泛癌分析确定ARHGAP23为胰腺腺癌的潜在生物标志物。
Mol Clin Oncol. 2023 Nov 3;19(6):100. doi: 10.3892/mco.2023.2696. eCollection 2023 Dec.
7
The HACE1 E3 ligase mediates RAC1-dependent control of mTOR signaling complexes.HACE1 E3 连接酶介导 RAC1 依赖性调控 mTOR 信号复合物。
EMBO Rep. 2023 Dec 6;24(12):e56815. doi: 10.15252/embr.202356815. Epub 2023 Oct 17.
8
Mechanobiology of cancer cell responsiveness to chemotherapy and immunotherapy: Mechanistic insights and biomaterial platforms.癌症细胞对化疗和免疫疗法反应的机械生物学:机制见解和生物材料平台。
Adv Drug Deliv Rev. 2023 May;196:114771. doi: 10.1016/j.addr.2023.114771. Epub 2023 Mar 6.
9
Cytoskeletal and Cytoskeleton-Associated Proteins: Key Regulators of Cancer Stem Cell Properties.细胞骨架及细胞骨架相关蛋白:癌症干细胞特性的关键调节因子
Pharmaceuticals (Basel). 2022 Nov 8;15(11):1369. doi: 10.3390/ph15111369.
10
Preclinical Efficacy and Toxicology Evaluation of RAC1 Inhibitor 1A-116 in Human Glioblastoma Models.RAC1抑制剂1A-116在人胶质母细胞瘤模型中的临床前疗效和毒理学评估
Cancers (Basel). 2022 Sep 30;14(19):4810. doi: 10.3390/cancers14194810.
Neurochem Res. 2017 May;42(5):1543-1554. doi: 10.1007/s11064-017-2213-0. Epub 2017 Mar 7.
4
Rho GTPases: Anti- or pro-neoplastic targets?Rho GTP酶:抗肿瘤还是促肿瘤靶点?
Oncogene. 2017 Jun 8;36(23):3213-3222. doi: 10.1038/onc.2016.473. Epub 2016 Dec 19.
5
Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells.Rac1-PAK1轴的药理学抑制可恢复人耐药乳腺癌细胞对他莫昔芬的敏感性。
Cell Signal. 2017 Jan;30:154-161. doi: 10.1016/j.cellsig.2016.12.002. Epub 2016 Dec 7.
6
WASP family proteins, more than Arp2/3 activators.WASP家族蛋白,比Arp2/3激活剂更多。
Biochem Soc Trans. 2016 Oct 15;44(5):1339-1345. doi: 10.1042/BST20160176.
7
Rac1/RhoA antagonism defines cell-to-cell heterogeneity during epidermal morphogenesis in nematodes.Rac1/RhoA拮抗作用决定了线虫表皮形态发生过程中的细胞间异质性。
J Cell Biol. 2016 Nov 21;215(4):483-498. doi: 10.1083/jcb.201604015. Epub 2016 Nov 7.
8
AZT exerts its antitumoral effect by telomeric and non-telomeric effects in a mammary adenocarcinoma model.在一个乳腺腺癌模型中,齐多夫定通过端粒效应和非端粒效应发挥其抗肿瘤作用。
Oncol Rep. 2016 Nov;36(5):2731-2736. doi: 10.3892/or.2016.5094. Epub 2016 Sep 15.
9
Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.Tiam1在乳腺浸润性导管癌中过表达的临床病理意义
BMC Cancer. 2016 Aug 25;16(1):681. doi: 10.1186/s12885-016-2724-0.
10
Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms.人类疾病中的Rac1:靶向Rac1信号调节机制的治疗潜力
Small GTPases. 2017 Jul 3;8(3):139-163. doi: 10.1080/21541248.2016.1211398. Epub 2016 Jul 21.